| INTRODUCTION
Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract. 1 Typically diagnosed in a person's late teens and early twenties, it can have a significant impact on health and quality of life domains. 2 The advent of biologic agents set in motion a paradigm shift in the treatment of Crohn's disease from a reactive approach, often culminating in multiple intestinal resections, to the selective application of a proactive "top-down" strategy to control disease activity. [3] [4] [5] [6] Therapeutic drug monitoring (TDM) has helped physicians refine the use of biologic agents such as infliximab (IFX), limiting drug exposure while achieving therapeutic effect. 7, 8 Several studies have suggested that higher trough IFX concentrations are associated with higher rates of clinical response 9, 10 Current practice suggests a target trough IFX concentration >3 lg/mL. 8 Recent studies suggest that higher IFX concentrations may be beneficial, particularly in patients with fistulising disease. 11, 12 Threshold adalimumab (ADA) concentrations are not as well defined as those for IFX but higher trough concentrations are associated with increased likelihood of clinical remission. 13, 14 Despite the progress made in the treatment of inflammatory bowel disease (IBD), there remain a substantial number of patients who do not respond to anti-TNF agents, either through primary nonresponse or secondary loss of response. 15, 16 Ustekinumab is a fully humanised IgG1 monoclonal antibody to the p40 subunit of IL-12/IL-23. 17, 18 This pathway has a role to play in the complex pathophysiology of Crohn's disease. 19 Ustekinumab has been approved for the treatment of patients with moderate-severely active Crohn's disease based on Phase III data. 20 In the UNITI-1 and UNITI-2 studies, induction was administered by weight-based dosing (approximately 6 mg/ kg), as a single intravenous (IV) infusion of ustekinumab or placebo.
The rates of clinical remission in UNITI-1 at Week 8 were higher in both patients who received 130 mg IV USK and 6 mg/kg IV ustek- 
| METHODS
A prospective cohort study was performed in a single academic cen- At induction, patients received 360 mg ustekinumab subcutaneously in 3 divided doses. The regimen is outlined below ( Table 1 ).
The interval between subsequent maintenance doses was at the discretion of the treating physician (who was blinded to the results of ustekinumab levels).
At each study visit, the following data were prospectively recorded; clinical symptoms, using the Harvey Bradshaw Index (HBI); haemoglobin (Hb), Albumin (Alb), C-reactive protein (CRP) and faecal calprotectin (FCP). Serum samples were taken prior to the administration of subcutaneous ustekinumab for the purposes of measuring trough drug levels. These samples were analysed by Sanquin Diagnostic Services by ELISA where the target (interleukin-12) is used to capture ustekinumab, and rabbit anti-ustekinumab for detection. 26 The primary outcome measures assessed were;
• Trough serum ustekinumab levels and proportion of patients in clinical remission (defined as Harvey Bradshaw Index ≤4) at Week
following subcutaneous ustekinumab induction
The secondary outcome measures were;
• 
| Ethics
The study protocol was reviewed and approved by the local research ethics committee. All patients provided written informed consent to participate in this study.
| RESULTS

| Patient characteristics
Nineteen patients were recruited. The median age was 36.2 years (IQR 25.4-40.8 years) and median disease duration was 18.9 years (5.9-23.2 years). The majority of patients had previously undergone a surgical resection (n = 13; 68.4%). Patient demographics and disease characteristics are outlined in Table 2 .
Each of the 19 patients included in this study had been treated previously with other biologic agents. All had been exposed to anti- Median Faecal calprotectin at baseline was elevated at 533 lg/g (IQR; 408-1908 lg/g).
| Induction therapy
The induction treatments with ustekinumab were successfully completed in 17/19 cases (90%). The cumulative induction dose for patients who completed induction was 360 mg ustekinumab 
| Clinical outcomes
At Week 0, the median Harvey Bradshaw Index was 5 (IQR; 2-8).
Nine of nineteen (47%) had a Harvey Bradshaw Index ≤4, one of whom was on steroids at induction. However, of those 9 patients, 6
had an elevated C-reactive protein and the remaining 3 had endo- 
| Trough ustekinumab concentrations
The median ustekinumab trough concentration at Week 1 was 
| Biochemical outcomes
There was a significant improvement in faecal calprotectin measurements from median 533 lg/g at baseline to 278 lg/g at Week 0
(P = 0.038) (Figure 3 ). However, only 1 patient with an elevated faecal calprotectin at baseline had a faecal calprotectin <50 lg/g by Week 8. No significant changes in Albumin or C-reactive protein from baseline to Week 8 were noted (Table 3 ). The median ustekinumab trough concentration in patients with a normal Week 8 faecal calprotectin (<200 lg/g) was 7.1 lg/mL (IQR 4.60-9.43 lg/mL), compared to a median of 6.1 lg/mL (3.9-9.7 lg/mL) in those with a persistently elevated Week 8 faecal calprotectin (P = 1.00).
| Adverse events
Subcutaneous ustekinumab was well tolerated. One patient (5.3%) developed a breast abscess 1 week after the first dose (180 mg) was Supplemental data from the UNITI-1 trial describe median Week 8 trough concentrations of 2.1 lg/mL (IQR 1-3.4 lg/mL) and 6.4 lg/mL (IQR 3.3-9.6 lg/mL) in the 130 mg and 6 mg/kg groups respectively. 20 The trough concentrations at Week 8 described here are comparable to those reported using intravenous induction at 6 mg/kg, suggesting that either formulation is effective in achieving detectable ustekinumab trough concentrations following induction.
We did not identify any independent factors such as Albumin, Creactive protein or body mass index (BMI), associated with achieving higher trough concentrations at Week 8. However, this pilot study was not powered to fully assess these factors. Within the limits of the study, there was no significant difference in Week 8 trough concentrations, clinical or biochemical outcomes detected between the groups treated with or without combination immunomodulators.
Ustekinumab has previously been reported to have low rates of immunogenicity. 20, 21, 30 Current literature suggests that the development of anti-drug antibodies may not be as significant a factor as with other biologic agents and therefore the added benefit of immunomodulator therapy must be investigated further. 
